COMMUNIQUÉS West-GlobeNewswire

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia
30/07/2019
LA JOLLA, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update
30/07/2019
Second Quarter and Recent Company Highlights: Consolidated Net Revenue Up 2% Compared to Second Quarter 2018 International Net Revenue Up 21% Compared to Second Quarter 2018 UK’s NICE Provided Positive Opinion for [...]
iCAD to Report Second Quarter 2019 Financial Results on Thursday, August 1
29/07/2019
NASHUA, N.H., July 29, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial [...]
Taconic Biosciences lance le premier modèle animal commercial de la NASH
29/07/2019
Ce nouveau modèle apporte des gains de temps aux chercheurs étudiant cette maladie dévastatrice RENSSELAER, N.Y., 29 juill. 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, un chef de file mondial dans la fourniture de [...]
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares
29/07/2019
BEDMINSTER, N.J., and DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American [...]
Cambium Networks Corporation Announces Second Quarter Fiscal 2019 Reporting Date
29/07/2019
ROLLING MEADOWS, Ill., July 29, 2019 (GLOBE NEWSWIRE) -- Cambium Networks Corporation (“Cambium”) (NASDAQ: CMBM), a leading provider of wireless broadband networking infrastructure solutions, today announced that it [...]
Rockwell Medical, Inc. to Discuss Second Quarter 2019 Financial Results on August 8, 2019
29/07/2019
WIXOM, Mich., July 29, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2019 second quarter financial results on [...]
Intuitive Appoints Amy L. Ladd, M.D. to its Board of Directors
29/07/2019
SUNNYVALE, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the appointment of Amy L [...]
Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH
29/07/2019
EDISON, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non [...]
Integra LifeSciences Acquires Arkis Biosciences Inc.
29/07/2019
Adds Unique Solution to Integra’s Neurocritical Care Offering PLAINSBORO, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, [...]
Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
29/07/2019
BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK ), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
29/07/2019
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 29, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second [...]
Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
29/07/2019
Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019 Phase 2/3 DYSTANCE 51 global, placebo-controlled study of suvodirsen initiated First topline data from PRECISION-HD clinical [...]
Silk Road Medical Reports Second Quarter 2019 Financial Results and Raises 2019 Outlook
29/07/2019
SUNNYVALE, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three [...]
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/07/2019
STAMFORD, Conn., July 29, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate [...]
Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019
29/07/2019
CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
Livongo Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
29/07/2019
MOUNTAIN VIEW, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO) today announced the closing of its initial public offering of 14,590,050 shares of its common stock at a price of $28.00 per [...]
Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results
29/07/2019
-- Launched Uncovering Rare Obesity to facilitate diagnosis of rare genetic disorders of obesity -- -- Announced positive opinion by EMA on Orphan Drug Designation for setmelanotide for the treatment of patients with [...]
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
29/07/2019
-Provides update in ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Enrolling in Phase 1/2 clinical trial of CTX110 ™ , targeting CD19+ malignancies- ZUG, Switzerland and [...]

Pages